


**Product Name** : BML-281  
**Cat. No.** : PC-60692  
**CAS No.** : 1045792-66-2  
**Molecular Formula** : C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>6</sub>  
**Molecular Weight** : 446.5  
**Target** : HDAC  
**Solubility** : 10 mM in DMSO



## Biological Activity

BML-281 (CAY10603) is a potent, selective **HDAC6** inhibitor with IC<sub>50</sub> of 0.002 nM, weakly inhibits HDAC3 (IC<sub>50</sub>=0.42 nM) and >50,000-fold selectivity over HDAC1/2/8/10.

BML-281 (CAY10603) blocks pancreatic cancer cell growth with IC<sub>50</sub> of <1 uM.

BML-281 (CAY10603) selectively reduces lamina propria B-cell infiltrate and suppresses CD19+ B lymphocyte influx into DSS-inflamed lamina propria, elicits broad-spectrum anti-inflammatory effects in DSS-induced colitis in mice.

## References

Lohman RJ, et al. *J Pharmacol Exp Ther*. 2016 Feb;356(2):387-96.

Do A, et al. *J Pharmacol Exp Ther*. 2017 Jan;360(1):140-151.

Kozikowski AP, et al. *J Med Chem*. 2008 Aug 14;51(15):4370-3.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com